{"id":"doi:10.1016/s0140-6736(23)01185-6","kind":"article","title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","authors":["Filip Krag Knop","Vanita R. Aroda","Ruben Duque do Vale","Thomas Holst‐Hansen","Peter Nørkjær Laursen","Julio Rosenstock","Domenica Rubino","William Timothy Garvey"],"author_count":8,"year":2023,"published":"2023-06-25","venue":"The Lancet","cited_by":430,"doi":"10.1016/s0140-6736(23)01185-6","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1016/s0140-6736(23)01185-6","archive_url":"https://space-kitty.com/papers/doi:10.1016/s0140-6736(23)01185-6","updated":null,"pmid":"37385278","pmcid":null,"openalex_id":"W4381953540","pdf_url":null,"abstract":null,"abstract_license":null,"license":null,"is_open_access":false,"retracted":false,"peer_reviewed":null,"categories":["Pharmacology and Obesity Treatment"],"details":null,"provenance":"openalex","attribution":"Metadata and citation counts: OpenAlex (CC0).","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[{"slug":"glp1-metabolic","title":"GLP-1 & Incretin Therapies: State of the Field (October 2026)","url":"https://space-kitty.com/dossiers/glp1-metabolic"}]}